Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Pentraxin 3 as a Novel Marker Predicting Congestive Heart Failure in Subjects With Acute Coronary Syndrome

  • Lee, Dong-Hyeon (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Jeon, Hui-Kyung (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • You, Ji-Han (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Park, Mi-Yeon (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Seung-Jae (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Sung-Sik (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Shim, Byung-Joo (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Choi, Yun-Seok (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Shin, Woo-Seung (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jong-Min (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Park, Chul-Soo (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Youn, Ho-Joong (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Chung, Wook-Sung (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jae-Hyung (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • Received : 2009.11.11
  • Accepted : 2010.02.05
  • Published : 2010.08.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Pentraxin 3 (PTX3) was shown to be elevated in the acute phase of acute myocardial infarction (AMI) and to have prognostic significance in AMI patients. The aim of this study was to estimate whether the value of PTX3 could be used as a prognostic biomarker, with the global registry of acute coronary events (GRACE) risk assessment tool, in patients with acute coronary syndrome (ACS). Subjects and Methods: Between July 2007 and June 2008, 137 patient subjects (mean age : 61${\pm}$12 years, M : F=108 : 29) with ACS who underwent coronary intervention, but did not have a prior percutaneous coronary intervention (PCI) and/or follow-up coronary angiogram, were enrolled. We estimated the allcause mortality or death/MI, in-hospital and to 6 months, using the GRACE risk scores and compared these estimates with serum PTX3 concentrations. Results: The serum PTX3 concentration showed a significant increase in ST segment elevation myocardial infarction (STEMI) greater than the unstable angina pectoris (UAP) group (2.4${\pm}$2.1 ng/mL vs. 1.3${\pm}$0.9 ng/mL, p= 0.017, respectively), but did not show a significant difference between non-ST segment elevation myocardial infarction (NSTEMI) and the UAP group (1.9${\pm}$1.4 ng/mL vs. 1.3${\pm}$0.9 ng/mL, p=0.083, respectively). The serum PTX3 concentration was closely related to death/MI in-hospital (r=0.242, p=0.015) and death/MI to 6 months (r=0.224, p=0.023), respectively. The serum PTX3 concentration was not related to all-cause mortality in-hospital (r=0.112, p=0.269) and to 6 months (r=0.132, p=0.191), respectively. Among the parameters determining the GRACE risk scores, the degree of Killip class in congestive heart failure (CHF) was independently associated with the supramedian PTX3 concentration [odds ratio: 2.229 (95% confidence interval: 1.038-4.787), p=0.040]. Conclusion: The serum PTX3 level provides important information for the risk stratification of CHF among the parameters determining the GRACE risk scores in subjects with ACS.

Keywords

References

  1. Noh HJ, Kwon NH, Joo SB. Severity of coronary atherosclerosis: influence of metabolic syndrome risk factor clustering and hs-CRP. Korean Circ J 2006;36:802-8.
  2. Doo YC, Park WJ, Park SH, et al. The optimal timing to measure C-reactive protein to predict cardiac events in patients with unstable angina. Korean Circ J 2001;31:290-6. https://doi.org/10.4070/kcj.2001.31.3.290
  3. Kim TI, Chae SC, Yang DH, et al. Short-term prognostic value of CRP in the patients with acute coronary syndrome. Korean Circ J 2000;30:1387-94.
  4. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6. https://doi.org/10.1016/S0140-6736(96)07591-5
  5. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105:800-3. https://doi.org/10.1161/hc0702.104126
  6. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10-4. https://doi.org/10.1161/01.ATV.0000015595.95497.2F
  7. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66. https://doi.org/10.1146/annurev.immunol.23.021704.115756
  8. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41. https://doi.org/10.1161/01.CIR.102.6.636
  9. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54. https://doi.org/10.1161/01.CIR.0000145167.30987.2E
  10. GRACE Investigators. Rationale and design of the GRACE (global registry of acute coronary events) project: a multinational registry of patients hospitalized with acute coronary syndrome. Am Heart J 2001;141:190-9. https://doi.org/10.1067/mhj.2001.112404
  11. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the global registry of acute coronary events (GRACE). Lancet 2002;359:373-7. https://doi.org/10.1016/S0140-6736(02)07595-5
  12. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53. https://doi.org/10.1001/archinte.163.19.2345
  13. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33. https://doi.org/10.1001/jama.291.22.2727
  14. Das R, Kilcullen N, Morrell C, Robinson MB, Barth JH, Hall AS. The British Cardiac Society Working Group definition of myocardial infarction: implications for practice. Heart 2006;92:21-6. https://doi.org/10.1136/hrt.2004.046441
  15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-121.
  16. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STElevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157.
  17. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329. https://doi.org/10.1161/CIRCULATIONAHA.107.188209
  18. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660. https://doi.org/10.1093/eurheartj/ehm161
  19. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-95. https://doi.org/10.1161/CIRCULATIONAHA.107.188208
  20. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209. https://doi.org/10.1016/j.jacc.2007.10.002
  21. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-43. https://doi.org/10.1136/hrt.47.3.239
  22. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit?: C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-50.
  23. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit?: the verdict is still out. Circulation 2006;113:2128-34. https://doi.org/10.1161/CIRCULATIONAHA.105.611350
  24. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81. https://doi.org/10.1016/j.ahj.2007.08.013
  25. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:19-22. https://doi.org/10.1016/j.ijcard.2007.07.168
  26. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7. https://doi.org/10.1161/01.ATV.0000252126.48375.d5
  27. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055-64. https://doi.org/10.1161/CIRCULATIONAHA.107.749234
  28. Kotooka N, Inoue T, Fujimatsu D, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008;197:368-74. https://doi.org/10.1016/j.atherosclerosis.2007.05.031

Cited by

  1. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome vol.28, pp.9, 2012, https://doi.org/10.3109/09513590.2011.652719
  2. PTX3 Is Located at the Membrane of Late Apoptotic Macrophages and Mediates the Phagocytosis of Macrophages vol.32, pp.2, 2010, https://doi.org/10.1007/s10875-011-9615-6
  3. Plasma Pentraxin 3 May Be a More Sensitive Marker of Inflammatory Response Than High-Sensitivity C-Reactive Protein After Bare-Metal Stent Compared to Drug-Eluting Stent Implantation vol.33, pp.5, 2013, https://doi.org/10.1089/jir.2012.0023
  4. The long pentraxin PTX3: a candidate anti-inflammatory mediator in cardiac surgery vol.28, pp.5, 2010, https://doi.org/10.1177/0267659113483799
  5. The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction vol.6, pp.1, 2010, https://doi.org/10.14740/cr375w
  6. Consolidated and emerging inflammatory markers in coronary artery disease vol.5, pp.1, 2010, https://doi.org/10.5493/wjem.v5.i1.21
  7. Elevated Plasma Pentraxin3 Levels and Its Association with Neovascular Age-related Macular Degeneration vol.23, pp.3, 2010, https://doi.org/10.3109/09273948.2014.891755
  8. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study vol.9, pp.5, 2010, https://doi.org/10.1177/1753944715578405
  9. The Time Course of Markers of Neutrophil Extracellular Traps in Patients Undergoing Revascularisation for Acute Myocardial Infarction or Stable Angina Pectoris vol.2016, pp.None, 2010, https://doi.org/10.1155/2016/2182358
  10. Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases vol.99, pp.None, 2017, https://doi.org/10.1016/j.vph.2017.10.003
  11. Correlation between single nucleotide polymorphisms in the 3 primer untranslated region of PTX3 and the risk of essential hypertension : A case-control study vol.100, pp.24, 2021, https://doi.org/10.1097/md.0000000000025937